Current Report · Items 2.02, 9.01 · 8-K

Royalty Pharma plc

RPRXNASDAQEQUITYCurrent

Results of Operations and Financial Condition

Filed Feb 11, 2025Accepted Feb 11, 2025, 7:38 AM ESTCIK 1802768Accession 0001193125-25-023988

Company context

Founded in 1996, Royalty Pharma is the largest buyer of biopharmaceutical royalties and a leading funder of innovation across the biopharmaceutical industry, collaborating with innovators from academic institutions, research hospitals and non-profits through small and mid-cap biotechnology companies to leading global pharmaceutical companies. Royalty Pharma has assembled a portfolio of royalties which entitles it to payments based directly on the top-line sales of many of the industry’s leading therapies. Royalty Pharma funds innovation in the biopharmaceutical industry both directly and indirectly - directly when it partners with companies to co-fund late-stage clinical trials and new product launches in exchange for future royalties, and indirectly when it acquires existing royalties from the original innovators. Royalty Pharma’s current portfolio includes royalties on more than 35 commercial products, including Vertex’s Trikafta, GSK’s Trelegy, Roche’s Evrysdi, Johnson & Johnson’s Tremfya, Biogen’s Tysabri and Spinraza, Servier’s Voranigo, AbbVie and Johnson & Johnson’s Imbruvica, Astellas and Pfizer’s Xtandi, Pfizer’s Nurtec ODT and Gilead’s Trodelvy, and 16 development-stage product candidates. For more information, visit www.royaltypharma.com.

Current securities

RPRXNASDAQ · EQUITY · Current

Recent company filings

Disclosure sections

Items 2.02, 9.01

Select an item to read the extracted section. The as-filed document remains the primary evidence.

Item 2.02Item 2.02 - Results of Operations

Item 2.02. Results of Operations and Financial Condition. On February 11, 2025, Royalty Pharma plc issued a press release announcing its financial results for the quarter and year ended December 31, 2024. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K. The information included in Item 2.02 of this Current Report on Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that Section and shall not be deemed incorporated by reference into any other filing under the Securities Act of 1933, as amended, or the Exchange Act, except as otherwise expressly stated in such filing.

Filed exhibits (1)

EX-99.1 (by filename) d929959dex991.htm

EX-99.1 2 d929959dex991.htm EX-99.1 EX-99.1 Exhibit 99.1 ROYALTY PHARMA REPORTS Q4 AND FULL YEAR 2024 RESULTS Portfolio Receipts of $742 million in Q4 2024 and $2,801 million for FY 2024 Royalty Receipts growth of 12% in Q4 2024 and 13% for FY 2024 ───────────────────────────────────────────────────────────────── Net cash provided by operating activities of $743 million in Q4 2024 and $2,769 million for FY 2024 Full year 2025 guidance: Portfolio Receipts expected to be $2,900 to $3,050 million excluding future transactions NEW YORK, NY, February 11, 2025 - Royalty Pharma plc (Nasdaq: RPRX) today reported financial results for the fourth quarter and full year 2024 and introduced full year 2025 guidance for Portfolio Receipts. “We had an incredibly successful 2024, delivering double-digit growth in Royalty Receipts, which was significantly above our initial guidance, and deploying $2.8 billion of capital on value-enhancing royalties” said Pablo Legorreta, Royalty Pharma’s founder and Chief Executive Officer. “We are very excited for the opportunities ahead as the fundamentals of our business have never been stronger. Additionally, we have already taken two majo…

Open exhibit ↗

Get the free weekly BCS email.